Akero Therapeutics, Inc. (AKRO)

Market Cap	4.50B +110.4%
Revenue (ttm)	n/a
Net Income	-292.82M
EPS	-3.74
Shares Out	82.32M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	15,312,254
Open	54.52
Previous Close	n/a
Day's Range	54.37 - 54.83
52-Week Range	21.34 - 58.40
Beta	-0.40
Analysts	Buy
Price Target	73.56 (+34.6%)
Earnings Date	Nov 7, 2025

About AKRO

Akero Therapeutics, Inc. engages in developing transformational treatments for patients with serious metabolic diseases in the United States. The company’s lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 20, 2019
• Employees: 63
• Stock Exchange: NASDAQ
• Ticker Symbol: AKRO
• Website: https://akerotx.com

Analyst Summary

According to 11 analysts, the average rating for AKRO stock is "Buy." The 12-month stock price target is $73.56, which is an increase of 34.60% from the latest price.

Price Target

$73.56

(34.60% upside)

Analyst Consensus: Buy